Association between metabolic syndrome and mortality among breast cancer survivors: a prospective cohort study
Frontiers in Endocrinology · 03.08.2026 · 17
DOI: 10.3389/fendo.2026.1854729 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Endocrinology, online erschienen am 03.08.2026. Verfasst von Ting Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Shaoxing Shangyu People's Hospital, Shaoxing, Zhejiang, China. Hauptthemen laut MEDLINE: Metabolic Syndrome, Breast Neoplasms, Cancer Survivors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolic syndrome (MetS) has been associated with elevated mortality risk and cardiovascular disease incident among the general population. However, evidence on its impact among breast cancer (BC) survivors remains limited.
Methods
BC survivors in the UK Biobank, a large-scale, population-based prospective cohort, were included in this study. MetS was defined as fulfilling at least three of the following criteria: (1) central obesity, (2) elevated triglycerides or taking lipid-lowering medication, (3) increased blood pressure, (4) elevated fasting blood glucose, and (5) reduced HDL cholesterol. The primary outcome was all-cause mortality, while the secondary outcomes were comorbidity incident. The associations between MetS with mortality and comorbidity incident were determined using Cox proportional regression by quantifying the hazard ratio (HR) and its 95% confidence interval (CI).
Results
After a median follow-up of 15.7 (interquartile range, 15.1 to 16.4) years, a total of 1,251 deaths were observed among 6,027 BC survivors, of whom 1,997 (33.1%) had MetS. MetS was significantly associated with all-cause mortality (HR, 1.23; 95% CI, 1.08 to 1.41, p = 0.002). Meanwhile, MetS was also significantly associated with elevated risk of myocardial infarction (MI; HR, 1.56; 95% CI, 1.02 to 2.40), atrial fibrillation (AF; HR, 1.61; 95% CI, 1.04 to 2.49), and chronic kidney disease (CKD; HR, 1.98 95% CI, 1.56 to 2.51) incident. Fatty acid metabolism and inflammation were identified as the potential mediating factors between MetS and mortality.
Conclusion
MetS was significantly associated with elevated mortality risk and incident of MI, AF, and CKD. The MetS–mortality association was potentially mediated by fatty acid metabolism and inflammation. Findings highlighted MetS as a potentially modifiable risk factor in BC survivors, underscoring the need for targeted metabolic management to improve long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, Shaoxing Shangyu People's Hospital, Shaoxing, Zhejiang, China.
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Zhang, T., Cai, X., Qian, S., & Huang, J. (2026). Association between metabolic syndrome and mortality among breast cancer survivors: a prospective cohort study. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1854729
Vancouver
Zhang T, Cai X, Qian S, Huang J. Association between metabolic syndrome and mortality among breast cancer survivors: a prospective cohort study. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1854729
BibTeX
@article{Zhang2026,
author = {Zhang, Ting and Cai, Xiaoni and Qian, Shaoqing and Huang, Jingxuan},
title = {Association between metabolic syndrome and mortality among breast cancer survivors: a prospective cohort study},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.1854729}
}
EUVIMED